Study Evaluating the Efficacy and Safety of AV5080 in Patients With Uncomplicated Influenza

PHASE3UnknownINTERVENTIONAL
Enrollment

700

Participants

Timeline

Start Date

January 15, 2022

Primary Completion Date

July 15, 2023

Study Completion Date

July 31, 2023

Conditions
Influenza
Interventions
DRUG

AV5080

oral hard gelatin capsules

OTHER

Placebo

Hard gelatin capsules with a white body

Trial Locations (6)

Unknown

Specialized Clinical Infectious Diseases Hospital, Krasnodar

Murmansk Regional Clinic named after P.A. Bayandin, Murmansk

Federal Research Center Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk

Center for the Prevention and Control of AIDS and Infectious Diseases, Saint Petersburg

First Saint Petersburg State Medical University named after I.I. Academician Pavlov, Saint Petersburg

Research Center Eco-safety, Saint Petersburg

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Viriom

INDUSTRY